Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia

Abstract

Hypopigmentation of the skin can develop in about one third of CML patients taking IM. Physicians taking care of CML patients should be aware of this and patients need to be warned before commencing IM, particularly in dark-skinned patients.